Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 411 to 420 of 996 total matches.
In Brief: Melamine
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008 (Issue 1297)
Hospital, Copenhagen
Dan M. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons ...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware,...
In Brief: New Propellants for Albuterol Metered-Dose Inhalers
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008 (Issue 1298)
of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York ...
Inhaled drugs for asthma are available in the US mainly in pressurized metered-dose inhalers (MDIs), which require a propellant, and dry powder inhalers, which do not. The chlorofluorocarbon (CFC) propellants in MDIs are being replaced by hydrofluoroalkane (HFA) propellants for environmental reasons: CFCs contribute to the depletion of the ozone layer. December 31, 2008 will be the last day that albuterol MDIs using CFC propellants can be sold in the US. The FDA is expected to announce a termination date for other CFC-containing products in the near future.Three HFA albuterol inhalers and one...
In Brief: Fluoroquinolones and Tendon Injuries
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008 (Issue 1300)
School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New ...
The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any fluoroquinolone, either while the drug is being taken or for up to several months afterwards.Fluoroquinolone-related tendon injury is rare; estimates for its incidence in the general population range from 0.14% to 0.4%. The risk is higher for patients >60 years old and for those taking corticosteroids. For patients with organ transplants, the incidence may be as high as 15%.1 A case-control...
In Brief: Different Diets
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009 (Issue 1308)
of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York ...
A recent article in the New England Journal of Medicine confirms something that others, including The Medical Letter (Treat Guidel Med Lett 2008; 6:23), have been saying for years: no particular combination of protein, carbohydrate and fat in the diet offers any advantage in losing weight. This randomized 2-year trial followed 800 overweight and obese subjects on low fat/average protein, low fat/high protein, high fat/average protein, and high fat/high protein diets. Carbohydrate intake varied from 35% (in the high fat/high protein diet) to 65% (in the low fat/average protein diet). All...
In Brief: Plan B for 17-Year Olds
The Medical Letter on Drugs and Therapeutics • May 18, 2009 (Issue 1312)
. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba ...
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B, taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception.2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B. Fetal malformations have not been associated with pregnancies that occurred...
In Brief: Injectable Paliperidone Palmitate for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba ...
Paliperidone palmitate (Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006.1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen.2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal), which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better...
Belimumab (Benlysta) for Systemic Lupus Erythematosus
The Medical Letter on Drugs and Therapeutics • Jun 13, 2011 (Issue 1366)
trial. Lancet 2011; 377:721.
5. R Furie et al. Belimumab, a BLyS-specific inhibitor, reduced
disease ...
Belimumab (Benlysta – Human Genome Sciences/GlaxoSmithKline) has been approved by the FDA for
treatment of adults with active, autoantibody-positive, systemic lupus erythematosus (SLE). It is the first biologic
agent approved for SLE and the first drug of any kind to be approved for this disease in >50 years.
Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain
The Medical Letter on Drugs and Therapeutics • May 14, 2012 (Issue 1390)
. Fentanyl nasal spray (Lazanda) for pain. Med Lett Drugs Ther
2011; 53:99.
3. R Rauck et al. Efficacy ...
The FDA has approved a sublingual spray formulation of
fentanyl (Subsys – Insys) for management of breakthrough
pain in adult cancer patients who are receiving
and are tolerant to opioid therapy (taking ≥60 mg/day of
oral morphine or the equivalent). Fentanyl is already
available in the US for intravenous, intrathecal, epidural,
transdermal and transmucosal use.
Electronic Cigarettes for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • Nov 26, 2012 (Issue 1404)
on desire to
smoke, withdrawal symptoms and cognition. Addict Behav
2012; 37:970.
7. R Polosa et al ...
Electronic cigarettes, also called e-cigarettes, are
battery-operated nicotine-delivery devices that
resemble tobacco cigarettes. They deliver vapor containing
a mixture of nicotine and either propylene glycol
or glycerol. E-cigarettes are widely available in
retail stores and on the internet in labeled strengths
ranging from zero to high levels of nicotine and in flavors
such as tobacco, mint, coffee, cherry, bubblegum,
and chocolate. They are advertised as a healthier
alternative to smoking a tobacco cigarette and,
although not FDA-approved, as a smoking cessation
tool.
QuilliChew ER - Extended-Release Chewable Methylphenidate Tablets
The Medical Letter on Drugs and Therapeutics • May 23, 2016 (Issue 1495)
are scored)
to a maximum dose of 60 mg.
1. Drugs for ADHD. Med Lett Drugs Ther 2015; 57:37.
2. R Abbas et ...
The FDA has approved a once-daily, extended-release
chewable tablet formulation of methylphenidate
(QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first
long-acting chewable formulation of the drug to be
marketed in the US. Immediate-release chewable
methylphenidate tablets (Methylin, and generics) have
been available since 2003.